Novartis

Fabrikstrasse 2, 4056 Basel
Novartis   link
Discipline: Pharmacology
Related:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

#display_name

Pharmacology - Health - Dec 6
Patients & Caregivers Healthcare Professionals Society & ESG Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate 1 -   QMF149 showed improvement in peak expiratory flow, exacerbation rates, rescue medication use versus mometasone furoate am
Pharmacology - Health - Dec 5

Patients & Caregivers Healthcare Professionals Society & ESG - Uniquely positioned with global scale, focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms 60 projects in Phase 2 pipeline with 10+ advancing into Phase 3 or pivotal tri

Pharmacology - Health - Dec 2

Patients & Caregivers Healthcare Professionals Society & ESG With more than 140 abstracts, Novartis continues its leadership in hematology innovation -   Data for MBG453, an innovative anti-TIM-3 immunotherapy, with decitabine on preliminary response rates in patients with high-risk MDS a

Pharmacology - Nov 21

Patients & Caregivers Healthcare Professionals Society & ESG - o   The Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) identifies and embraces technology that aims to improve mobility and daily life for people living with MS o   Applications are open worldwide to the t

Pharmacology - Health - Nov 15

Patients & Caregivers Healthcare Professionals Society & ESG Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications 1 -   Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63 vs 2.98) and

Pharmacology - Health - Nov 13

Patients & Caregivers Healthcare Professionals Society & ESG - The strategy is aligned with the Novartis Access Principles, which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally -   A newly formed sub-Saharan Africa u

Health - Pharmacology - Nov 12

Patients & Caregivers Healthcare Professionals Society & ESG Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when switching to biosimilar etanercept

Health - Dec 5

Patients & Caregivers Healthcare Professionals Society & ESG - Basel, December 5, 2019 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation ("Purchaser"), has commenced a cash tender offer to pu

Pharmacology - Health - Nov 24

Patients & Caregivers Healthcare Professionals Society & ESG Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal and remain

Pharmacology - Health - Nov 17

Patients & Caregivers Healthcare Professionals Society & ESG - Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan 1 -   Entresto, compared to valsartan, demonstrated reduced risk in total heart fai

Pharmacology - Health - Nov 15

Patients & Caregivers Healthcare Professionals Society & ESG - If approved, Mayzent (siponimod) will be the first and only oral treatment specifically indicated for patients with active secondary progressive multiple sclerosis (SPMS) in Europe ) -   CHMP opinion is based on the Phase III EX

Pharmacology - Health - Nov 12

Patients & Caregivers Healthcare Professionals Society & ESG - 42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52 -   PREVENT is the largest ever study of

Pharmacology - Health - Nov 11

Patients & Caregivers Healthcare Professionals Society & ESG - The FLIGHT- FXR phase IIb study showed tropifexor, a highly potent non-bile acid FXR agonist, produces robust and dose-dependent reductions in hepatic fat and alanine aminotransferase compared to placebo at 12 weeks -   These da



Job Offers

» Job Offer: Novartis

Last job offers



website preview

Link

Medicine and Life Sciences

This site uses cookies and analysis tools to improve the usability of the site. More information. |